PD-1 expression on tumor cells: a new target for cancer therapy

被引：0
|
作者：
Tone, Mari [1 ,2 ]
Iwahori, Kota [1 ,2 ,3 ]
机构：
[1] Osaka Univ, Grad Sch Med, Dept Resp Med & Clin Immunol, Osaka, Japan
[2] Osaka Univ, Grad Sch Med, Dept Clin Res Tumor Immunol, Osaka, Japan
[3] Osaka Univ, Grad Sch Med, Dept Clin Res Tumor Immunol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan
来源：
TRANSLATIONAL LUNG CANCER RESEARCH | 2024年 / 13卷 / 01期
关键词：
Anti programmed death-1 antibody (anti-PD-1 antibody); cancer stemness; non-small cell lung cancer (NSCLC); chemoresistance; PATHWAYS;
D O I：
10.21037/tlcr-23-683
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：186 / 189
页数：4
相关论文
共 50 条
  • [41] PD-1/PD-L1 expression in colorectal cancer and its implications for apoptosis and tumor immune evasion
    Gasser, Martin
    Grimm, Martin
    Nichiporuk, Ekaterina
    Bueter, Marco
    Lutz, Jens
    Lebedeva, Tatiana
    Koenigshausen, Matthias
    Thalheimer, Andreas
    Thiede, Arnulf
    Heemann, Uwe
    Meyer, Detlef
    Waaga-Gasser, Ana Maria
    CANCER RESEARCH, 2006, 66 (08)
  • [42] Overexpression of CD155 is associated with PD-1 and PD-L1 expression on immune cells, rather than tumor cells in the breast cancer microenvironment
    Wang, Rui-Bin
    Li, Yu-Chen
    Zhou, Quan
    Lv, Shu-Zhen
    Yuan, Ke-Yu
    Wu, Jiang-Ping
    Zhao, Yan-Jie
    Song, Qing-Kun
    Zhu, Bin
    WORLD JOURNAL OF CLINICAL CASES, 2020, 8 (23) : 5935 - 5943
  • [43] Overexpression of CD155 is associated with PD-1 and PD-L1 expression on immune cells, rather than tumor cells in the breast cancer microenvironment
    Rui-Bin Wang
    Yu-Chen Li
    Quan Zhou
    Shu-Zhen Lv
    Ke-Yu Yuan
    Jiang-Ping Wu
    Yan-Jie Zhao
    Qing-Kun Song
    Bin Zhu
    World Journal of Clinical Cases, 2020, (23) : 5935 - 5943
  • [44] Blocking the PD-1/PD-L1 axis for cancer therapy
    Drake, C.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S12 - S13
  • [45] PD-1 AND PD-L1 EXPRESSION ON THE PROGNOSIS OF OVARIAN CANCER
    Li, R. P.
    Li, W. Y.
    Guo, Y. Z.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2019, 33 (04): : 1161 - 1166
  • [46] Combination therapy with PD-1 or PD-L1 inhibitors for cancer
    Hayashi, Hidetoshi
    Nakagawa, Kazuhiko
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (05) : 818 - 830
  • [47] Combination therapy with PD-1 or PD-L1 inhibitors for cancer
    Hidetoshi Hayashi
    Kazuhiko Nakagawa
    International Journal of Clinical Oncology, 2020, 25 : 818 - 830
  • [48] PD-1 receptor expression by NK cells after contact with tumor cells: from origin to function
    Merabet, Anis
    Westrelin, Florian
    Vieillard, Vincent
    M S-MEDECINE SCIENCES, 2024, 40 (6-7): : 576 - 577
  • [49] Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy
    Taube, J. M.
    Klein, A.
    Brahmer, J. R.
    Xu, H.
    Pan, X.
    Kim, J.
    Chen, L.
    Pardoll, D. M.
    Topalian, S. L.
    Anders, R. A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2014, 134 : S92 - S92
  • [50] Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
    Lipson, Evan J.
    Lilo, Mohammed T.
    Ogurtsova, Aleksandra
    Esandrio, Jessica
    Xu, Haiying
    Brothers, Patricia
    Schollenberger, Megan
    Sharfman, William H.
    Taube, Janis M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
12345